Matthew Bouchonville, MD
Endocrinology, Diabetes & Metabolism · Albuquerque, NMNPI 1144369141
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,182 of the $7,266 with a category attached, or 85.1%. It is spread thinly across 18 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 132 payments — averaging $55.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Novo Nordisk$1K
- Amgen$835
- Pfizer$765
- Lilly USA, LLC$527
- plus $2K from 12 others
What the payments were for
- Speaking & faculty fees$1,00014%
- Travel & lodging$761%
- Food & beverage$6,18285%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 61 | $1,414 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,114 |
| Novo Nordisk | 18 | $1,025 |
| Amgen(2 entities) | 8 | $835 |
| Pfizer | 9 | $765 |
| Lilly USA, LLC | 13 | $527 |
| Xeris Pharmaceuticals, Inc. | 4 | $258 |
| Tandem Diabetes Care, Inc. | 3 | $216 |
| Abbott | 3 | $168 |
| BETA Bionics, Inc. | 1 | $142 |
| Corcept Therapeutics | 1 | $123 |
| AstraZeneca | 1 | $122 |
| Boehringer Ingelheim | 1 | $121 |
| Averitas Pharma Inc. | 1 | $121 |
| Medtronic | 1 | $120 |
| Ultragenyx Pharmaceutical Inc. | 2 | $99 |
| Bayer | 1 | $81 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$479
- iLet Bionic Pancreas$427
- EVENITY$392
- PREVNAR 20$363
- Ozempic$219
- FREESTYLE LIBRE 3$124
- Korlym$123
- ABRYSVO$122
- JARDIANCE$121
- Qutenza$121
- GVOKE HYPOPEN$121
- MINIMED 780G$120
- MOUNJARO$113
- GVOKE PFS$102
How this compares
$7,266 in reported general payments places this provider in the 85th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $19,055 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 25 | $17,426 |
| NovologInsulin Aspart | 19 | $3,934 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,480 |
| Insulin Aspart FlexpenInsulin Aspart | 12 | $3,197 |
| HumalogInsulin Lispro | 12 | $2,654 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $2,142 |
| Hydrocortisone | 22 | $681 |
| Levothyroxine Sodium | 66 | $677 |
| Fludrocortisone Acetate | 18 | $414 |
| Gabapentin | 14 | $293 |
| Ezetimibe | 12 | $234 |
| Lisinopril | 14 | $63 |
| Atorvastatin Calcium | 18 | $41 |
| Dexamethasone Sodium Phosphate | 14 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,025 | $22,98835 claims |
| Lilly USA, LLCHumalog | $527 | $2,65412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Albuquerque
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- Jeremy GleesonAlbuquerque$46K
- David SchadeAlbuquerque$16K
- Mansi MehtaAlbuquerque$15K
- Teodor DuroAlbuquerque$6K
- Ivan PinonAlbuquerque$5K
- Namrata JannareddyAlbuquerque$4K
- Anita Sloan-GarciaAlbuquerque$4K
- Lisa EreifejAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.